Thus, in addition to clarifying the mechanistic relationship between DPN and skeletal disease in vivo, we believe our results can inform the future use of SARM1 inhibitors as a novel strategy to promote diabetic neuroskeletal health. Here, SARM1 is linked to bone disorder.